Impact of Non-weight-dependent Low-dose Somatropin on Bone Accrual in Childhood-onset GH Deficient in the Transition: an 18-month Randomized Controlled Trial

Overview

Journal J Pediatr (Rio J)

Specialty Pediatrics

Date 2024 Dec 21

PMID 39709185

Authors

Valesca Mansur Kuba

Antonia B S Castro

Claudio Leone

Durval Damiani

Affiliations

Soon will be listed here.

Abstract

Objective: Discontinuation of growth hormone therapy (rhGH) upon completion of linear growth may adversely affect bone mineral density and content (BMD/BMC) in adolescents with childhood-onset GH deficiency (CO-GHD) and predisposition to osteoporosis. Although the benefits of weight-dependent somatropin high doses over bone gain are established, little is known about fixed low doses. We analyzed the impact of non-weight-based low-dose somatropin on bone accrual during the transition among CO-DGH patients, treated since childhood.

Methods: Lumbar spine (LS) and whole-body (WB) BMD and BMC were measured at baseline and after 18 months in 54 adolescents (age: 16.8 ± 1.6 years). They were retested and reclassified as GH sufficient (GHS, n = 28) and GH insufficient. The last group was later randomized to use rhGH (GH on; n = 15) or no treatment (GH off, n = 11) in this single-center open-label study. The average dose of rhGH was 0.5 ± 0.18 mg/day.

Results: When comparing the groups, the GH off group had a lower percentage change in LS BMD than the GHS (0.53 % ± 5.9 vs. 4.42 % ± 4.1, respectively, p < 0.04). However, in the analysis of the GH on and off subgroups, the LS BMC percentage change was higher in the GH on (11.02 % ± 10.12 vs. 2.05 % ± 10.31, respectively, p < 0.04).

Conclusion: Non-weight-based low-dose somatropin withdrawal for 18 months limits bone accrual in LS of CO-DGH subjects in transition, predisposing them to osteoporosis in adult life.

References

Mauras N, Pescovitz O, Allada V, Messig M, Wajnrajch M, Lippe B . Limited efficacy of growth hormone (GH) during transition of GH-deficient patients from adolescence to adulthood: a phase III multicenter, double-blind, randomized two-year trial. J Clin Endocrinol Metab. 2005; 90(7):3946-55. DOI: 10.1210/jc.2005-0208. View

Drake W, Carroll P, Maher K, Metcalfe K, Camacho-Hubner C, Shaw N . The effect of cessation of growth hormone (GH) therapy on bone mineral accretion in GH-deficient adolescents at the completion of linear growth. J Clin Endocrinol Metab. 2003; 88(4):1658-63. DOI: 10.1210/jc.2002-021541. View

Spielhagen C, Schwahn C, Moller K, Friedrich N, Kohlmann T, Moock J . The benefit of long-term growth hormone (GH) replacement therapy in hypopituitary adults with GH deficiency: results of the German KIMS database. Growth Horm IGF Res. 2010; 21(1):1-10. DOI: 10.1016/j.ghir.2010.10.005. View

Cook D, Rose S . A review of guidelines for use of growth hormone in pediatric and transition patients. Pituitary. 2012; 15(3):301-10. DOI: 10.1007/s11102-011-0372-6. View

Boot A, van der Sluis I, Krenning E, de Muinck Keizer-Schrama S . Bone mineral density and body composition in adolescents with childhood-onset growth hormone deficiency. Horm Res. 2009; 71(6):364-71. DOI: 10.1159/000223422. View

Johansson H, Oden A, Kanis J, McCloskey E, Morris H, Cooper C . A meta-analysis of reference markers of bone turnover for prediction of fracture. Calcif Tissue Int. 2014; 94(5):560-7. DOI: 10.1007/s00223-014-9842-y. View

Yuen K, Biller B, Radovick S, Carmichael J, Jasim S, Pantalone K . AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF GROWTH HORMONE DEFICIENCY IN ADULTS AND PATIENTS TRANSITIONING FROM PEDIATRIC TO ADULT CARE. Endocr Pract. 2019; 25(11):1191-1232. DOI: 10.4158/GL-2019-0405. View

Fors H, Bjarnason R, Wirent L, Albertsson-Wikland K, Bosaeust L, Bengtsson B . Currently used growth-promoting treatment of children results in normal bone mass and density. A prospective trial of discontinuing growth hormone treatment in adolescents. Clin Endocrinol (Oxf). 2002; 55(5):617-24. DOI: 10.1046/j.1365-2265.2001.01386.x. View

Geffner M . Growth hormone replacement therapy: transition from adolescence to adulthood. J Clin Res Pediatr Endocrinol. 2011; 1(5):205-8. PMC: 3005750. DOI: 10.4274/jcrpe.v1i5.205. View

10.

Conway G, Szarras-Czapnik M, Racz K, Keller A, Chanson P, Tauber M . Treatment for 24 months with recombinant human GH has a beneficial effect on bone mineral density in young adults with childhood-onset GH deficiency. Eur J Endocrinol. 2009; 160(6):899-907. DOI: 10.1530/EJE-08-0436. View

11.

Underwood L, Attie K, Baptista J . Growth hormone (GH) dose-response in young adults with childhood-onset GH deficiency: a two-year, multicenter, multiple-dose, placebo-controlled study. J Clin Endocrinol Metab. 2003; 88(11):5273-80. DOI: 10.1210/jc.2003-030204. View

12.

Eastell R, Pigott T, Gossiel F, Naylor K, Walsh J, Peel N . DIAGNOSIS OF ENDOCRINE DISEASE: Bone turnover markers: are they clinically useful?. Eur J Endocrinol. 2017; 178(1):R19-R31. DOI: 10.1530/EJE-17-0585. View

13.

Rizzoli R, Bianchi M, Garabedian M, McKay H, Moreno L . Maximizing bone mineral mass gain during growth for the prevention of fractures in the adolescents and the elderly. Bone. 2009; 46(2):294-305. DOI: 10.1016/j.bone.2009.10.005. View

14.

Grimberg A, DiVall S, Polychronakos C, Allen D, Cohen L, Quintos J . Guidelines for Growth Hormone and Insulin-Like Growth Factor-I Treatment in Children and Adolescents: Growth Hormone Deficiency, Idiopathic Short Stature, and Primary Insulin-Like Growth Factor-I Deficiency. Horm Res Paediatr. 2016; 86(6):361-397. DOI: 10.1159/000452150. View

15.

Lee Y, Choi Y, Yoo H, Lee Y, Shin C, Choi H . Metabolic Impacts of Discontinuation and Resumption of Recombinant Human Growth Hormone Treatment during the Transition Period in Patients with Childhood-Onset Growth Hormone Deficiency. Endocrinol Metab (Seoul). 2022; 37(2):359-368. PMC: 9081298. DOI: 10.3803/EnM.2021.1384. View

16.

Attanasio A, Shalet S . Growth hormone and the transition from puberty into adulthood. Endocrinol Metab Clin North Am. 2007; 36(1):187-201. DOI: 10.1016/j.ecl.2006.11.002. View

17.

Maeda S, Borba V, Camargo M, Silva D, Borges J, Bandeira F . Recommendations of the Brazilian Society of Endocrinology and Metabology (SBEM) for the diagnosis and treatment of hypovitaminosis D. Arq Bras Endocrinol Metabol. 2014; 58(5):411-33. DOI: 10.1590/0004-2730000003388. View

18.

Mauras N . GH use in the transition of adolescence to adulthood. Endocr Dev. 2010; 18:109-125. DOI: 10.1159/000316131. View

19.

Baroncelli G, Bertelloni S, Sodini F, Saggese G . Longitudinal changes of lumbar bone mineral density (BMD) in patients with GH deficiency after discontinuation of treatment at final height; timing and peak values for lumbar BMD. Clin Endocrinol (Oxf). 2004; 60(2):175-84. DOI: 10.1046/j.1365-2265.2003.01949.x. View

20.

Ahmid M, Perry C, Ahmed S, Shaikh M . Growth hormone deficiency during young adulthood and the benefits of growth hormone replacement. Endocr Connect. 2016; 5(3):R1-R11. PMC: 5002964. DOI: 10.1530/EC-16-0024. View